Skip to content

Cohort Study of Childhood Nephrotic Syndrome

Shanghai Clinical Cohort Study on Childhood Nephrotic Syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117567
Enrollment
Unknown
Registered
2026-01-26
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Nephrotic Syndrome

Interventions

Observation Group:NA

Sponsors

Children's Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age Range: Participants must be between 0 and 18 years of age (inclusive), with no restrictions on gender. 2. Diagnostic Criteria: Must exhibit nephrotic-range proteinuria, defined as either a urine protein/creatinine ratio >= 2.0 mg/mg, a 24-hour urinary protein excretion >= 50 mg/kg, or a urine protein dipstick result of >= 3+. This must be accompanied by at least one of the following: hypoalbuminemia (serum albumin < 30 g/L) or pitting edema (in cases where serum albumin results are unavailable). 3. First Diagnosis or Ongoing Treatment: Includes newly diagnosed cases, as well as cases admitted due to relapse or for treatment (including cases transferred from other institutions or previously diagnosed at partner institutions). All these cases should be enrolled to construct a comprehensive disease spectrum. 4. Informed Consent: Written informed consent must be obtained from the parent or legal guardian. 5. Good Compliance: Cases where the patient is expected to complete the follow-up plan and cooperate with data collection.

Exclusion criteria

Exclusion criteria: 1. Secondary Nephrotic Syndrome: Cases with a clear etiology of systemic diseases, such as systemic lupus erythematosus, Henoch-Schönlein purpura, diabetic nephropathy, or infection-associated glomerulonephritis. 2. Ineligible Cases: Patients who are unable to comply with follow-up requirements or for whom informed consent could not be obtained.

Design outcomes

Primary

MeasureTime frame
Time to First Relapse;

Secondary

MeasureTime frame
Number of relapses per patient during 24- week follow-up after completion of steroid therapy;

Countries

China

Contacts

Public ContactXu Hong

Children's Hospital of Fudan University

hxu@shmu.edu.cn+86 21 64932825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026